Treatment of patients with immune-related adverse events after checkpoint inhibitors with extracorporeal photopheresis (ECP): a retrospective analysis and translational studies
- Conditions
- Immune-related adverse events (colitis, hepatitis, dermatitis, arthralgia) after treatment with immune checkpoint inhibitors (antibodies against PD-1, PD-L1 and CTLA4).
- Registration Number
- DRKS00026642
- Lead Sponsor
- niversitätsklinikum Freiburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Enrolling by invitation
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
age 18 years or older
written informed consent
previous Treatment with anti-PD-1, anti-PD-L1 or anti-CTLA4 antibodies
development of irAE after treatment with immune checkpoint inhibitors
treatment of irAE with ECP
Exclusion Criteria
previous treatment with ECP in the medical history
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Expression of cell surface markers and cytokines on leukocytes from patients treated with extracorporeal photopheresis for immune-related adverse events after checkpoint inhibitor treatment. The analysis will be performed by flow cytometry on multiple time points between week 1 and 52 after beginning of ECP.
- Secondary Outcome Measures
Name Time Method Correlations between immune phenotype and clinical outcome